Tiziana Gains $3.4M Boost for Neurodegenerative Trials
Company Announcements

Tiziana Gains $3.4M Boost for Neurodegenerative Trials

Tiziana Life Sciences (TLSA) has released an update.

Tiziana Life Sciences has secured $3.4 million in non-dilutive funding, bolstering its financial position as it progresses with Phase 2 trials for its novel intranasal therapy foralumab in multiple sclerosis and Alzheimer’s Disease. The company, known for its pioneering nasal drug delivery technology, aims to enhance treatment efficacy and patient safety compared to traditional intravenous methods. This financial infusion will support Tiziana’s ongoing research and development efforts in neurodegenerative disease treatment.

For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Highlights Advancements at BIO-Europe 2024
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Announces $10 Million Share Offering
TipRanks Auto-Generated NewsdeskTiziana Life Sciences Reports Promising Obesity Therapy Results
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App